Crexont (IPX203) vs Parcopa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Crexont (IPX203)
Marketed by Amneal Pharmaceuticals and partners
NCT03670953 · Phase 3 · completed
The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).
Next expected readout: February 2027 · NCT07138560 (registry estimate)
Reported efficacy
Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081) (met)
Result source: NCT03670953
Parcopa
Rights held by UCB; US product discontinued
NCT00139867 · Phase 3 · completed
The study used randomization and a conventional carbidopa/levodopa comparator, but it was open-label and focused on treatment preference rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Onset of action: time to a 30% decrease in UPDRS Motor Exam (Part III) total score after identical doses of Parcopa and Sinemet: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)
Result source: NCT00139880
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Crexont (IPX203) | Parcopa |
|---|---|---|
| OFF time, change | —Not reported | —Not posted · NCT00139880 |
| ON time without troublesome dyskinesia, change | —Not reported | —Not posted · NCT00139880 |
| UPDRS Part III, change | —Not reported | —Not posted · NCT00139880 |
| MDS-UPDRS Part II, change | —Not reported | —Not posted · NCT00139880 |
OFF time, change
- Crexont (IPX203)
- —Not reported
- Parcopa
- —Not posted · NCT00139880
ON time without troublesome dyskinesia, change
- Crexont (IPX203)
- —Not reported
- Parcopa
- —Not posted · NCT00139880
UPDRS Part III, change
- Crexont (IPX203)
- —Not reported
- Parcopa
- —Not posted · NCT00139880
MDS-UPDRS Part II, change
- Crexont (IPX203)
- —Not reported
- Parcopa
- —Not posted · NCT00139880
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Crexont (IPX203): 2 of 4 rows · Parcopa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Crexont (IPX203) | Parcopa |
|---|---|---|
| Dropout rate | —IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result—IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result—IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 2%IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result3.1%IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 0%a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | dyskinesia 6.8% nausea 4.9% dry mouth 4.2% NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more resultnausea 4.3% anxiety 2.7% dizziness 2.3% NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Crexont (IPX203)
Parcopa
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · Parcopa's landscape